SuperworthMcKesson MCK
- Market cap
- $116.7B
- PE
- 26.8×
- 10y median 24.7×
- Forward PE
- 21.6×
- 10y median 13.3×
- Price to sales
- 0.3×
- EV/EBIT
- 17.9×
- Revenue, 12 months
- $411B
- +9% on a year ago
- Net margin
- 1.1%
- Free cash flow yield
- 5.5%
McKesson trades at 26.8× trailing earnings, near its ten-year median. Revenue was $411B over the last twelve months, up 9% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $77.2B+10% | $80.9B+15% | $76.4B+11% | $79.3B+6% | $93.7B+21% | $95.3B+18% | $90.8B+19% | $97.8B+23% | $103.2B+10% | $106.2B+11% | $96.3B+6% | $105.4B+8% | |
| Cost of revenue | $74.1B+11% | $77.7B+16% | $72.8B+11% | $76.1B+7% | $90.4B+22% | $92B+18% | $87.2B+20% | $94.5B+24% | $99.6B+10% | $102.5B+11% | $92.3B+6% | $101.7B+8% |
| Gross profit | $3.1B−1% | $3.2B−1% | $3.6B+17% | $3.2B+4% | $3.2B+6% | $3.3B+4% | $3.6B+2% | $3.3B+4% | $3.5B+9% | $3.7B+12% | $4B+11% | $3.7B+12% |
| SG&A | $2.1B+7% | $2.5B+32% | $2.2B+12% | $2B+7% | $2.5B+20% | $2B−19% | $2B−10% | $2.2B+10% | $2.1B−17% | $2B+0% | $1.8B−9% | $2.3B+3% |
| $951M−15% | $642M−48% | $1.2B+24% | $1B−7% | $578M−39% | $1.2B+91% | $1.6B+31% | $1B+1% | $1.4B+143% | $1.6B+32% | $2.1B+35% | $1.3B+27% | |
| Interest expense | $61M+11% | $64M−7% | $80M+1% | $75M+60% | $78M+28% | $67M+5% | $45M−44% | $49M−35% | $74M−5% | $63M−6% | $61M+36% | $77M+57% |
| Pre-tax income | $916M−26% | $612M−58% | $1.2B+26% | $1.1B−1% | $534M−42% | $1.2B+100% | $1.5B+30% | $1.1B−3% | $1.4B+161% | $1.6B+33% | $2.1B+40% | $1.3B+25% |
| $213M−21% | −$18M | $340M+221% | $124M+32% | $247M+16% | $298M | $209M−39% | $220M+77% | $232M−6% | $380M+28% | $270M+29% | $276M+26% | |
| Net income | $664M−28% | $589M−45% | $791M+1% | $915M−5% | $241M−64% | $879M+49% | $1.3B+59% | $784M−14% | $1.1B+361% | $1.2B+35% | $1.7B+34% | $614M−22% |
| $4.92−23% | $4.42−42% | $6.01+5% | $7.00−0% | $1.87−62% | $6.95+57% | $10.00+66% | $6.25−11% | $8.92+377% | $9.59+38% | $13.69+37% | $5.15−18% | |
| 134.8M−7% | 133.3M−6% | 131.7M−4% | 130.7M−4% | 129.3M−4% | 126.6M−5% | 126M−4% | 125.5M−4% | 124.4M−4% | 123.7M−2% | 122.9M−3% | 119.2M−5% |
Net income: 5 periods, Q4 FY09 to Q3 FY11: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY09 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY09 to Q4 FY26: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY18 and Q4 FY19: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q2 FY27 | $109.9B | $108.9B to $110.6B | $10.72 | $10.56 to $10.99 | 10 |
| Q3 FY27 | $113.2B | $112.2B to $113.9B | $10.91 | $10.34 to $11.35 | 10 |
| Q4 FY27 | $103.2B | $102.3B to $104B | $13.09 | $12.93 to $13.22 | 8 |
| Q1 FY28 | $111.9B | $110.9B to $112.8B | $11.62 | $11.47 to $11.73 | 8 |
| Q2 FY28 | $115.4B | $114.4B to $116.3B | $12.30 | $12.15 to $12.42 | 8 |
| Q3 FY28 | $118.9B | $117.8B to $119.8B | $12.63 | $12.48 to $12.76 | 8 |
| Q4 FY28 | $108.3B | $107.3B to $109.1B | $14.14 | $13.97 to $14.28 | 9 |
| Q1 FY29 | $115.7B | $114.7B to $116.6B | $13.98 | $13.81 to $14.12 | 9 |
Peers
Companies in Healthcare nearest McKesson's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MCKMcKesson | $116.7B | 26.8× | 24.7× | 21.6× | 0.3× | +9% | 1.1% |
| SYKStryker | $117.8B | 31.8× | 41.2× | 19.3× | 4.6× | +8% | 14.4% |
| CVSCVS Health | $119.5B | 24.7× | 16.2× | 11.5× | 0.3× | +7% | 1.2% |
| MDTMedtronic | $122B | 23.4× | 28.2× | 15.9× | 3.3× | +10% | 13.9% |
| BMYBristol-Myers Squibb | $125.6B | 13.5× | 19.9× | 10.4× | 2.6× | +3% | 18.9% |
| VRTXVertex Pharmaceuticals | $132.8B | 30.5× | 28.6× | 27.0× | 10.6× | +10% | 35.0% |
| HCAHCA Healthcare | $101.5B | 15.7× | 13.9× | 15.3× | 1.3× | +7% | 8.8% |
| ELVElevance Health | $95.4B | 19.6× | 17.6× | 16.1× | 0.5× | +6% | 2.5% |
| ISRGIntuitive Surgical | $159.8B | 54.7× | 69.3× | 37.5× | 13.8× | +20% | 25.5% |
| DHRDanaher | $162B | 40.9× | 34.2× | 25.4× | 6.5× | +5% | 15.9% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| Peer median | $120.8B | 24.1× | 24.1× | 16.0× | 3.9× | +8% | 15.2% |
Investors who own it
Investors we follow who held McKesson at the end of Jun 30, 2026, from their 13F filings.
- Stephen MandelLone Pine Capital0.3% of portfoliotrimmed
More on McKesson
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .